"Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACE) Event and Type 2 Diabetes Mellitus"

Purpose:
If the study drug Aleglitazar can reduce the risk of having a cardiovascular event in men or women with type 2 diabetes such as heart attack or stroke. Also, how the study drug effects blood sugar levels and cholesterol levels.    

IRB#: HUM00040196
Principal Investigator: Rodica Pop-Busui, MD, PhD
Study Coordinator: Cynthia Plunkett, RNC, CCRC, 734-936-8065 or cplunket@umich.edu
Sponsored by: Hoffmann-LaRoche Inc.

ELIGIBILITY CRITERIA:

• This study is seeking:  Males or females with type 2 diabetes who have been hospitalized for an acute coronary syndrome event (heart attack, unstable chest pain) within the preceding 6 weeks
• Age range: 18 years and older
• Medication: Cannot be taking oral steroids or fibrate drugs

Exclusion list is long and includes:

• Cannot have cancer with the exception of basal-cell occurring >2 years prior to participation
• Cannot have any life-threatening illness
• Cannot have elevated triglycerides >400
• Cannot have congestive heart failure class II-IV
  

All clinic visits are completed at Domino's Farms.

All study related tests and procedures are free. Subjects receive a new glucose meter and glucose strips for the duration of the study.

"Epidemiology of Heterogeneity in Type 2 Diabetes"

IRB#: HUM00008813
(click on the IRB# to see full study description in the UM Clinical Studies Database)

Principal Investigator: Massimo T. Pietropaolo, MD
Study Coordinators: Cynthia Plunkett, RNC, CCRC, 734-936-8065 or cplunket@umich.edu

ELIGIBILITY CRITERIA:

• Age range: 40–65 years old
• This study is seeking: Patients with specified condition (type 2 diabetes)

Other eligibility factors:

• Be diagnosed with type 2 diabetes
• Be on insulin therapy or metformin or combined insulin and metformin therapy
• Cannot be treated with oral TZD agents
• Have no history of liver disease
• Must not be pregnant

Compensation: Compensation for completion of study varies, depending on extent of involvement in the study.

"Studying a Treament Improving Neuropathy in Type 2 Diabetes"

IRB#: HUM00018940
(click on the IRB# to see full study description in the UM Clinical Studies Database)

Principal Investigator: Rodica Pop-Busui, MD, PhD
Study Coordinator: Cathy Martin, MS, APRN, BC-ADM, CDE, 734-936-6465 or martinc@umich.edu

ELIGIBILITY CRITERIA:

• Age range: 18–70 years old
• Medication: Taking medication
• This study is seeking: Patients with specified condition (type 2 diabetes)

Other eligibility factors:

• HbA1c between 7 and 10%
• Not taking any of the following medications: Insulin, Byetta, Januvia
• Mild to moderate peripheral neuropathy

Compensation: $25.00 per visit